Salamanca

• A randomized, double-blind, placebo-controlled, multicenter, adaptive phase III trial to investigate the efficacy and safety of vilobelimab … Ended
  2023-506250-20-00 5 2023-12-11 ulcerative pyoderma gangrenosum
• A Study to Evaluate CC-486 in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Cancer Partic … Ended
  2023-503427-26-00 3 2023-11-10 Myeloid malignancies with moderate or severe hepatic impairment or nor
• A study to test whether spesolimab helps people with a skin disease called hidradenitis suppurativa Ended
  2022-501074-19-00 10 2023-10-13 Hidradenitis suppurativa
• A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced HR Positive and HER2-Negative BC Ended
  2023-503903-27-00 4 2023-10-11 metastatic or locally advanced Hormone Receptor positive and Human Epi
• A study to investigate safety and efficacy with SAR445514 in participants with relapsed/refractory multiple myeloma (RRMM) and relapsed/refr … Ended
  2022-502057-33-00 7 2023-10-02 Relapsed/refractory multiple myeloma
• Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma (ALPHA2) Ended
  2022-501927-25-00 4 2023-09-29 Large B-Cell Lymphoma (LBCL)
• Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to … Ended
  2022-501918-55-00 4 2023-09-12 Mild Alzheimer's disease
• Study to Evaluate the Efficacy and Safety of Intranasal BPL-003 in Patients with Treatment Resistant Depression Ended
  2024-513457-70-00 4 2023-09-08 Treatment-Resistant Depression (TRD)
• APTIVATE Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients with … Ended
  2023-503244-14-00 7 2023-08-11 Relapsed or Refractory Acute Myeloid Leukemia (AML)
• An 18-month study to assess joint outcomes in patients with haemophilia A or B on prophylaxis with efmoroctocog alfa or eftrenonacog alfa Ended
  2022-502921-16-00 6 2023-07-21 Hemophilia A and B
• Biomarker Phase II Study Of Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer. Ended
  2024-511292-15-00 4 2023-05-25 Advance Radioactive-Iodine Refractory Differentiated Thyroid Cancer
• Phase 1b study to evaluate MK 0482 for Relapsed/Refractory AML/CMML Ended
  2023-503580-42-00 3 2023-05-16 Active CNS leukemia.
• Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial – Follow Up Long Term Extension (IMPAHCT-FUL) Ended
  2023-508735-31-00 5 2023-05-05 Pulmonary Arterial Hypertension (PAH)
• A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell … Ended
  2022-501259-10-00 4 2023-04-14 Relapsed/Refractory Waldenstrom Macroglobulinemia (WM)
• A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell … Ended
  2022-501260-18-00 4 2023-04-14 Relapsed/refractory Richter Transformation (RT)
• A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancie … Ended
  2022-501261-46-00 4 2023-04-14 Relapsed/Refractory Burkitt Lymphoma (BL)
• A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell … Ended
  2022-501262-21-00 4 2023-04-14 Relapsed/Refractory Hairy Cell Leukemia
• A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Cardiomyopathy Ended
  2023-506352-24-00 5 2023-04-13 Non-obstructive Hypertrophic Cardiomyopathy
• Prophylaxis of venous thromboembolic disease with LMWH (TINzaparin) in patients with metastatic colorectal cancer who start the first line o … Ended
  2023-508860-31-00 5 2023-02-28 Stage IV colon or rectal adenocarcinoma (mCRC).
• A trial in patients with blood cancer and lymphatic system cancer looking at finding the optimal dose of BMF-219 Ended
  2024-515744-23-00 1 2023-02-15 Relapsed or refractory (R/R) Acute lymphoblastic leukemia (ALL), R/R A
• Efficacy of [18F]florbetaben PET for diagnosis of cardiac AL amyloidosis Ended
  2022-500186-27-00 5 2023-01-11 ATTR Amyloidosis
• Phase 3 Study of Bepirovirsen in Nucleos(t)ide Analogue-treated Participants with Chronic Hepatitis B (B-Well 1) Ended
  2023-504239-41-00 5 2023-01-09 Hepatitis B, Chronic
• Seamless Phase 2/3 Study of Ibrutinib With Rituximab in Relapsed/Refractory Mantle Cell Lymphoma Ended
  2023-503618-64-00 4 2022-11-16 Relapsed/Refractory Mantle Cell Lymphoma
• MK-4280A versus Physician’s Choice Chemotherapy in PD-(L)1-refractory, relapsed/refractory Classical Hodgkin Lymphoma Ended
  2023-503615-14-00 4 2022-09-29 Relapsed or Refractory Classical Hodgkin Lymphoma

Showing 385–408 of 470 trials